In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 316
- 试验地点
- 1
- 主要终点
- Number of patients with BMI not measured
研究概览
简要总结
This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months)
- •Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study
排除标准
- •Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded
研究组 & 干预措施
liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg
干预措施: liraglutide (Drug)
结局指标
主要结局
Number of patients with BMI not measured
时间窗: Within 6 months before date of the first prescription
Number of patients with BMI above or equal to 30 kg/m^2
时间窗: Less than 6 months before date of first prescription
Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity
时间窗: Less than 6 months before date of first prescription
Dysglycaemia (Type 2 Diabetes Mellitus \[T2DM\] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities
Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities
时间窗: Less than 6 months before date of first prescription
Dysglycaemia (Type 2 Diabetes Mellitus \[T2DM\] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities.
Number of patients with BMI below 27 kg/m^2
时间窗: Less than 6 months before date of first prescription
次要结局
- Number of patients with liraglutide 1.2 or 1.8 mg prescriptions with dose information of 3.0 mg per day(From date of first prescription until 24 months)
- Number of patients with liraglutide 1.2 or 1.8 mg prescriptions and indication of weight management(From date of first prescription until 24 months)
- Number of patients with liraglutide 3.0 mg prescriptions who have reached a dose of 3.0 mg(By 12 weeks after first prescription date)
- Number of patients with liraglutide 3.0 mg prescriptions and other GLP-1 receptor agonists prescribed during continued treatment with liraglutide 3.0 mg(From date of first prescription until 24 months)
- Number of patients with continued treatment with liraglutide 3.0 mg(From date of first prescription until 0-6 weeks; 7-12 weeks; 13-18 weeks; 19-24 months)